Skip to main content
. 2018 May 1;197(9):1164–1176. doi: 10.1164/rccm.201703-0660OC

Figure 5.

Figure 5.

Effect of blocking C5a on bone metastasis formation of A549M1 cells. (A) Experimental regimen for the treatment of A549M1-injected mice with 10 mg/kg intraperitoneally of the anti-C5a l-aptamer AON-D21 (n = 7) or the control aptamer revAON-D21 (n = 8). (B) Quantification of BLI in hindlimbs 26 days after intracardiac inoculation. (C) Quantification of metastatic area by X-ray imaging. (D) Tumor burden assessed in hematoxylin and eosin–stained sections (Day 26). (E) Representative images of bioluminescence imaging (Day 26). (F) Representative X-ray images (top row), microcomputed tomography scans (middle row), and hematoxylin and eosin–stained histologic sections (bottom row) of each group (Day 26); arrows indicate osteolytic lesions. Data are presented as medians and interquartile ranges. Differences among experimental groups were analyzed using the Mann-Whitney U test. *P < 0.05; ***P < 0.001. C5a = cleaved complement component of C5; i.c. = intracardiac.